Hilary P Bagshaw1, David Ly1, Gita Suneja1, Randy L Jensen1,2, Dennis C Shrieve1. 1. University of Utah Radiation Oncology, 1950 Circle of Hope, Room 1570, Salt Lake City, UT 84112, USA. 2. University of Utah Neurosurgery, 175 North Medical Drive East, Salt Lake City, UT 84132, USA.
Abstract
PURPOSE: To examine the effectiveness of stereotactic radiosurgery (SRS) for melanoma brain metastases, as the optimal management is unknown. MATERIALS AND METHODS: Patients with melanoma brain metastases treated between 1999 and 2013 with SRS as initial management were reviewed. Local control (LC), intracranial progression free survival, and overall survival were evaluated using the Kaplan Meier analysis and logistic regression. RESULTS: 185 patients were identified with 435 treated brain metastases. 76% of metastases were controlled, with a median freedom from local failure of 23.4 months. Higher SRS dose (p=0.001) and smaller tumor volume (p=0.0007) were associated with improved LC on univariate analysis, but on multivariate analysis only smaller tumor volume remained significant (p=0.047). At analysis, 7.6% of patients were alive and the median time to death after SRS was 7.8 months. CONCLUSIONS: SRS is an effective primary treatment for melanoma brain metastases. There was no benefit combining SRS and surgery or whole brain radiotherapy.
PURPOSE: To examine the effectiveness of stereotactic radiosurgery (SRS) for melanoma brain metastases, as the optimal management is unknown. MATERIALS AND METHODS: Patients with melanoma brain metastases treated between 1999 and 2013 with SRS as initial management were reviewed. Local control (LC), intracranial progression free survival, and overall survival were evaluated using the Kaplan Meier analysis and logistic regression. RESULTS: 185 patients were identified with 435 treated brain metastases. 76% of metastases were controlled, with a median freedom from local failure of 23.4 months. Higher SRS dose (p=0.001) and smaller tumor volume (p=0.0007) were associated with improved LC on univariate analysis, but on multivariate analysis only smaller tumor volume remained significant (p=0.047). At analysis, 7.6% of patients were alive and the median time to death after SRS was 7.8 months. CONCLUSIONS: SRS is an effective primary treatment for melanoma brain metastases. There was no benefit combining SRS and surgery or whole brain radiotherapy.
Authors: Douglas Kondziolka; Juan J Martin; John C Flickinger; David M Friedland; Adam M Brufsky; Joseph Baar; Sanjiv Agarwala; John M Kirkwood; L Dade Lunsford Journal: Cancer Date: 2005-12-15 Impact factor: 6.860
Authors: Dirk Rades; Andre Pluemer; Theo Veninga; Patrick Hanssens; Juergen Dunst; Steven E Schild Journal: Cancer Date: 2007-11-15 Impact factor: 6.860
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Manmeet Ahluwalia; Mir A Ali; Rushikesh S Joshi; Eun Suk Park; Birra Taha; Ian McCutcheon; Veronica Chiang; Angela Hong; Georges Sinclair; Jiri Bartek; Clark C Chen Journal: Neurooncol Adv Date: 2020-11-12